Most Liquid Pharmaceuticals Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1NMRA Neumora Therapeutics, Common
267.57 M
(0.14)
 11.60 
(1.60)
2ELTX Elicio Therapeutics
11.02 M
 0.11 
 4.34 
 0.48 
3TAK Takeda Pharmaceutical Co
533.53 B
(0.14)
 1.00 
(0.14)
4NVO Novo Nordisk AS
37.47 B
(0.21)
 2.94 
(0.61)
5MRK Merck Company
12.69 B
(0.09)
 1.24 
(0.11)
6BMY Bristol Myers Squibb
9.12 B
 0.08 
 2.02 
 0.16 
7SNY Sanofi ADR
6.9 B
(0.05)
 1.60 
(0.08)
8JNJ Johnson Johnson
5.37 B
(0.14)
 0.97 
(0.14)
9NVS Novartis AG ADR
4.64 B
(0.26)
 1.05 
(0.27)
10AZN AstraZeneca PLC ADR
4.52 B
(0.15)
 1.60 
(0.23)
11GSK GlaxoSmithKline PLC ADR
3.72 B
(0.14)
 1.37 
(0.19)
12ZTS Zoetis Inc
3.58 B
(0.13)
 1.36 
(0.17)
13RDY Dr Reddys Laboratories
2.93 B
(0.05)
 1.52 
(0.08)
14PFE Pfizer Inc
2.85 B
(0.08)
 1.45 
(0.12)
15TEVA Teva Pharma Industries
2.22 B
 0.10 
 3.94 
 0.38 
16LLY Eli Lilly and
2.07 B
(0.16)
 2.16 
(0.34)
17RPRX Royalty Pharma Plc
1.47 B
 0.11 
 1.95 
 0.21 
18ARVN Arvinas
1.27 B
(0.11)
 4.27 
(0.49)
19CGC Canopy Growth Corp
1.23 B
(0.18)
 5.31 
(0.98)
20OGN Organon Co
706 M
(0.03)
 2.21 
(0.07)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).